Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.70 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.70 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.70 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3437398 | 0.87 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL17607319 | 0.86 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082124 | 0.85 | GUCY1B2 (0.74) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL10330251 | 0.82 | GUCY1B2 (0.64) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15068748 | 0.82 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437270 | 0.82 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL29778216 | 0.82 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL29831577 | 0.82 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL250991 | 0.82 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL26318509 | 0.82 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20170298055-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298055-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| WO-2017136309-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016044445-A2 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298055-A1 | sGC STIMULATORS | GUCY1B1, GUCY1A1, PRKG2 | GUCY1B2 5/4885GUCY1A2 6/4885GUCY1A1 2/4885 |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | GLS2, GPR119, PRKG1 | GUCY1B2 16/4885GUCY1A2 9/4885GUCY1A1 8/4885 |
| US-20210161893-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | GLS2, GPR119, PRKG1 | GUCY1B2 16/4885GUCY1A2 9/4885GUCY1A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.